Antibody drug conjugates—A new bioanalytical/analytical challenge 

By Alan Breau, Ph.D., Vice President of Bioanalytical/Analytical Sciences, MPI Research, Inc. and Kevin Meyer, Principal Scientist, Perfinity Biosciences 

Antibody drug conjugates (ADCs) link precisely targeted antibodies to cytotoxic small molecule drugs with the goal of improving both the safety and efficacy of chemotherapeutics. Pivotal clinical trials of trastuzumab‐DM1 for women with treatment resistant HER2‐positive breast cancer and of SGN‐35 for relapsed/refractory Hodgkin's lymphoma represent the vanguard of several dozen ADCs currently in various stages of clinical development. According to Fred Regnier, Purdue University's John H. Law Distinguished Professor of Chemistry, Principal Investigator for the Purdue/IU Analytical Proteomics Team, and founder of Perfinity Biosciences, "The emergence of new isolation methods paired with stable isotope coding and mass spectrometry measurement of proteins, modified proteins, and their tryptic digests provides an unprecedented level of specificity and quantification in examining their
structure, relative activity, and degradation in biological systems."

Read the whole article here.